Yes, and this is common in clinical practice
There are a number of stage 3 substages, based on how thick the tumor is, whether or not its ulcerated, and how far it has spread
Efficacy In the original phase 3 randomized trials for obesity, average weight reduction compared to placebo has ranged from 5.3 % to 17.8 % after 5672 weeks (Table 1), with improvements in several obesity-related risks and complications [[13], [14], [15]]
Beyond restriction risk, there are other ways these medications can complicate eating disorder recovery
The tirzepatide before and after results and comparable retatrutide data suggest that the glucagon receptor component produces additional fat loss beyond what dual agonist therapy achieves, particularly for visceral fat
Long-term follow-up of children conceived through assisted reproductive technology